Literature DB >> 15767436

Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.

Emily J Platt1, Danielle M Shea, Patrick P Rose, David Kabat.   

Abstract

By selecting the R5 human immunodeficiency virus type 1 (HIV-1) strain JR-CSF for efficient use of a CCR5 coreceptor with a badly damaged amino terminus [i.e., CCR5(Y14N)], we previously isolated variants that weakly utilize CCR5(Delta18), a low-affinity mutant lacking the normal tyrosine sulfate-containing amino-terminal region of the coreceptor. These previously isolated HIV-1(JR-CSF) variants contained adaptive mutations situated exclusively in the V3 loop of their gp120 envelope glycoproteins. We now have weaned the virus from all dependency on the CCR5 amino terminus by performing additional selections with HeLa-CD4 cells that express only a low concentration of CCR5(Delta18). The adapted variants had additional mutations in their V3 loops, as well as one in the V2 stem (S193N) and four alternative mutations in the V4 loop that eliminated the same N-linked oligosaccharide from position N403. Assays using pseudotyped viruses suggested that these new gp120 mutations all made strong contributions to use of CCR5(Delta18) by accelerating a rate-limiting CCR5-dependent conformational change in gp41 rather than by increasing viral affinity for this damaged coreceptor. Consistent with this interpretation, loss of the V4 N-glycan at position N403 also enhanced HIV-1 use of a different low-affinity CCR5 coreceptor with a mutation in extracellular loop 2 (ECL2) [i.e., CCR5(G163R)], whereas the double mutant CCR5(Delta18,G163R) was inactive. We conclude that loss of the N-glycan at position N403 helps to convert the HIV-1 envelope into a hair-trigger form that no longer requires strong interactions with both the CCR5 amino terminus and ECL2 but efficiently uses either site alone. These results demonstrate a novel functional role for a gp120 N-linked oligosaccharide and a high degree of adaptability in coreceptor usage by HIV-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767436      PMCID: PMC1061536          DOI: 10.1128/JVI.79.7.4357-4368.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

2.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism.

Authors:  B Chesebro; K Wehrly; J Nishio; S Perryman
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 7.  CD4 activation of HIV fusion.

Authors:  Q J Sattentau
Journal:  Int J Cell Cloning       Date:  1992-11

8.  Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.

Authors:  M Thali; C Furman; E Helseth; H Repke; J Sodroski
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

9.  Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.

Authors:  D Kabat; S L Kozak; K Wehrly; B Chesebro
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread.

Authors:  K Toohey; K Wehrly; J Nishio; S Perryman; B Chesebro
Journal:  Virology       Date:  1995-10-20       Impact factor: 3.616

View more
  19 in total

1.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

2.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

3.  Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

4.  Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.

Authors:  Koree W Ahn; Michael J Root
Journal:  J Biol Chem       Date:  2017-07-10       Impact factor: 5.157

5.  Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.

Authors:  Andreas Jekle; Milloni Chhabra; Adriane Lochner; Sonja Meier; Eugene Chow; Michael Brandt; Surya Sankuratri; Nick Cammack; Gabrielle Heilek
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

6.  Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.

Authors:  Emily J Platt; James P Durnin; David Kabat
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.

Authors:  Cleo G Anastassopoulou; Thomas J Ketas; Rafael S Depetris; Antonia M Thomas; Per Johan Klasse; John P Moore
Journal:  Virology       Date:  2011-02-26       Impact factor: 3.616

8.  Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.

Authors:  Olga Latinovic; Kate Schneider; Henryk Szmacinski; Joseph R Lakowicz; Alonso Heredia; Robert R Redfield
Journal:  Antiviral Res       Date:  2014-10-24       Impact factor: 5.970

9.  Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.

Authors:  Felix G Hermann; Lisa Egerer; Frances Brauer; Christian Gerum; Harald Schwalbe; Ursula Dietrich; Dorothee von Laer
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.

Authors:  Emily J Platt; James P Durnin; Ujwal Shinde; David Kabat
Journal:  J Mol Biol       Date:  2007-09-12       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.